Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 372

1.

BRAF, a target in melanoma: implications for solid tumor drug development.

Flaherty KT, McArthur G.

Cancer. 2010 Nov 1;116(21):4902-13. doi: 10.1002/cncr.25261. Review.

2.

Targeting BRAF in melanoma: biological and clinical challenges.

MandalĂ  M, Voit C.

Crit Rev Oncol Hematol. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003. Review.

PMID:
23415641
3.

Biological challenges of BRAF inhibitor therapy.

Puzanov I, Burnett P, Flaherty KT.

Mol Oncol. 2011 Apr;5(2):116-23. doi: 10.1016/j.molonc.2011.01.005. Review.

4.

BRAF inhibitors and melanoma.

Flaherty KT.

Cancer J. 2011 Nov-Dec;17(6):505-11. doi: 10.1097/PPO.0b013e31823e5357. Review.

PMID:
22157295
5.

Novel inhibitors in the treatment of metastatic melanoma.

Kalinsky K, Haluska FG.

Expert Rev Anticancer Ther. 2007 May;7(5):715-24. Review.

PMID:
17492934
6.

The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Haluska F, Pemberton T, Ibrahim N, Kalinsky K.

Semin Oncol. 2007 Dec;34(6):546-54. Review.

PMID:
18083378
7.

Targeting oncogenic drivers and the immune system in melanoma.

McArthur GA, Ribas A.

J Clin Oncol. 2013 Feb 1;31(4):499-506. doi: 10.1200/JCO.2012.45.5568.

PMID:
23248252
8.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
9.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327.

PMID:
21343559
10.

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Nissan MH, Solit DB.

Curr Oncol Rep. 2011 Dec;13(6):479-87. doi: 10.1007/s11912-011-0198-4. Review.

PMID:
21997758
11.

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.

Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825.

12.

Narrative review: BRAF opens the door for therapeutic advances in melanoma.

Flaherty KT.

Ann Intern Med. 2010 Nov 2;153(9):587-91. doi: 10.7326/0003-4819-153-9-201011020-00008. Review.

PMID:
21041578
13.

BRAF inhibitors in cancer therapy.

Hertzman Johansson C, Egyhazi Brage S.

Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Review.

PMID:
24325952
14.

Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.

Acosta AM, Kadkol SS.

Arch Pathol Lab Med. 2016 Nov;140(11):1290-1296. Review.

PMID:
27788045
15.

New drugs in melanoma: it's a whole new world.

Eggermont AM, Robert C.

Eur J Cancer. 2011 Sep;47(14):2150-7. doi: 10.1016/j.ejca.2011.06.052. Review.

PMID:
21802280
16.

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.

Wang AX, Qi XY.

IUBMB Life. 2013 Sep;65(9):748-58. doi: 10.1002/iub.1193. Review.

17.

[Modern methods of molecular targeted therapy for disseminated melanoma].

Novik AV, Protsenkol SA, Semenova AI, Latipova DKh, A S Zhabina, Akhaeva ZY.

Vopr Onkol. 2015;61(2):297-302. Review. Russian.

PMID:
26087614
18.

BRAF in melanoma: current strategies and future directions.

Salama AK, Flaherty KT.

Clin Cancer Res. 2013 Aug 15;19(16):4326-34. doi: 10.1158/1078-0432.CCR-13-0779. Review.

19.

Emerging Raf inhibitors.

McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.

Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Review.

PMID:
19715444
20.

BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.

Alcalá AM, Flaherty KT.

Clin Cancer Res. 2012 Jan 1;18(1):33-9. doi: 10.1158/1078-0432.CCR-11-0997.

Items per page

Supplemental Content

Support Center